Repair Biotechnologies is pioneering a Cholesterol Degrading Platform (CDP) designed to address the critical health issue of atherosclerosis, a condition characterized by the buildup of cholesterol-based plaques in arteries, which is a leading cause of cardiovascular diseases. The CDP aims to not only halt the progression of atherosclerosis but to actively reverse it by safely degrading excess cholesterol in targeted cells. This innovative approach has shown promising results in preclinical studies, where a single treatment in mouse models led to a significant reduction of atherosclerotic plaque by 48%. The platform is modular, allowing for potential applications across various medical conditions linked to cholesterol accumulation, including familial hypercholesterolemia and metabolic dysfunction-associated steatohepatitis (MASH).

The CDP's therapeutic potential extends beyond just cardiovascular health; it is being developed to treat a range of conditions where excess cholesterol is a contributing factor. Current treatments, such as statins, primarily focus on lowering cholesterol levels but do not effectively reduce existing plaque burden. In contrast, Repair Biotechnologies' CDP therapy has demonstrated the ability to improve cardiovascular function and reduce plaque size significantly, offering a more effective solution for patients suffering from atherosclerosis and related disorders. The company is advancing its CDP technology towards clinical trials, with a focus on both common and rare conditions driven by cholesterol dysregulation.

United States

Repair Biotechnologies is a preclinical biotechnology company focused on developing drugs for cholesterol and aging-related diseases. Our first-in-class Cholesterol Degrading Platform (CDP) technology is aimed at reversing atherosclerosis, familial hypercholesterolemias, and other conditions in which excess or modified cholesterol drives pathology.

Repair Biotechnologies

Company Details